#United States #Bethlehem #B. Braun #Piperacillin #Tazobactam

B. Braun Medical Inc. Launches Innovative Antibiotic Delivery System

B. Braun Medical Inc., a prominent name in smart infusion therapy and pain management, has made headlines with the launch of Piperacillin and Tazobactam in its unique DUPLEX® Drug Delivery System. This potent antibiotic combination stands as one of the most frequently utilized injectable treatments in the United States.

An Overview of the Launch

The newly introduced product is available in three formulations: 2.25 g/50 mL, 3.375 g/50 mL, and 4.5 g/100 mL. This launch follows recent accolades, including the Nurse Approved Certification for the DUPLEX Drug Delivery System that encompasses a complete range of IV solutions and plastic irrigation containers. The certification demonstrates B. Braun’s dedication to innovation tailored for nursing practices and usability.

The DUPLEX® Drug Delivery System

The DUPLEX system is designed for seamless operation. It features a ready-to-activate, two-compartment container that ensures medication and diluent remain separate until it's time for administration. Users only need to fold, squeeze, and shake the container to reconstitute the medication at the bedside. This streamlined process effectively reduces overall preparation time by almost four minutes per dose, which significantly enhances efficiency compared to traditional compounding methods and other systems like the Baxter Mini-Bag Plus.

Importantly, this modern delivery solution not only maximizes efficiency but also enhances safety. The closed-system design minimizes contamination risks and medication errors, protecting medication integrity while ensuring cohesive use of the diluent and drug combination. Notably, the DUPLEX system decreases the likelihood of medication mistakes by nearly 54% compared to conventional methods, addressing a critical need for accuracy in healthcare settings.

Commitment to Healthcare Professionals

Ellen Menard, Corporate Vice President of Marketing Pharma at B. Braun Medical, commented on the significance of this launch, stating, “The introduction of Piperacillin and Tazobactam in the DUPLEX® Drug Delivery System underscores our commitment to equipping healthcare professionals with efficient antibiotic options.”
This innovative product is engineered to optimize resources, alleviate waste, and enhance the overall workflow vital for pharmacies and nursing teams handling high-demand antibiotics.

B. Braun’s future looks promising as Piperacillin and Tazobactam marks the beginning of several anticipated injectable medications planned for launch in the U.S. The company's dedication to expanding its pharmaceutical portfolio aims to meet the increasing demands for critical medications by patients across various healthcare settings.

Important Safety Information

Indications and Usage

Piperacillin and Tazobactam for Injection, in combination with Sodium Chloride Injection, is indicated for various serious bacterial infections, including intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections, and community-acquired pneumonia.

Contraindications

It is critical to note that patients with a known allergy to any penicillins, cephalosporins, or beta-lactamase inhibitors should refrain from using this product.

About B. Braun Medical Inc.

Established in Bethlehem, Pennsylvania, B. Braun Medical Inc. partners with healthcare professionals to ensure effective patient care through safe infusion therapy and pharmaceutical products. With over 8,500 employees across North America and part of a global workforce exceeding 64,000, B. Braun remains committed to enhancing patient outcomes by sharing expertise and addressing the critical challenges in healthcare.

For additional information about the B. Braun portfolio and the DUPLEX Drug Delivery System, visit their website and stay tuned for the latest updates on their innovative solutions in the pharmaceutical landscape.